Patient characteristics in training and test cohorts
| Variables . | All patients (N = 10 480) . | Training cohort (n = 7860) . | Test cohort (n = 2620) . | P . |
|---|---|---|---|---|
| Underlying disease | .35 | |||
| Acute myeloid leukemia | 5811 (55.4) | 4344 (55.3) | 1467 (56.0) | |
| Acute lymphoblastic leukemia | 2466 (23.5) | 1873 (23.8) | 593 (22.6) | |
| Myelodysplastic syndromes | 1801 (17.2) | 1333 (17.0) | 468 (17.9) | |
| CML | 402 (3.8) | 310 (3.9) | 92 (3.5) | |
| Patient age, median (range), y | 49 (18-70) | 49 (18-70) | 49 (18-70) | .44 |
| Patient age ≥50 y | 5154 (49.2) | 3861 (49.1) | 1293 (49.4) | .84 |
| Donor age, median (range), y | 33 (0-69) | 33 (0-69) | 33 (0-68) | .33 |
| Donor age ≥50 y | 1181 (11.3) | 889 (11.3) | 292 (11.1) | .83 |
| Patient sex, male | 6112 (58.3) | 4575 (58.2) | 1537 (58.7) | .70 |
| Donor sex, male | 6318 (60.3) | 4748 (60.4) | 1570 (59.9) | .66 |
| Female donor to male recipient | 2325 (22.2) | 1742 (22.2) | 583 (22.3) | .94 |
| Recipient/donor CMV serology | .75 | |||
| Positive/positive | 4329 (41.3) | 3236 (41.2) | 1093 (41.7) | |
| Positive/negative | 4201 (40.1) | 3143 (40.0) | 1058 (40.4) | |
| Negative/positive | 754 (7.2) | 575 (7.3) | 179 (6.8) | |
| Negative/negative | 1196 (11.4) | 906 (11.5) | 290 (11.1) | |
| Disease risk (high) | 4240 (40.5) | 3134 (39.9) | 1106 (42.2) | .036 |
| PS (poor) | 718 (6.9) | 563 (7.2) | 155 (5.9) | .029 |
| Stem cell source | .55 | |||
| Bone marrow | 5920 (56.5) | 4418 (56.2) | 1502 (57.3) | |
| PBSC | 1853 (17.7) | 1405 (17.9) | 448 (17.1) | |
| CB | 2707 (25.8) | 2037 (25.9) | 670 (25.6) | |
| Transplant from unrelated donor | 7898 (75.4) | 5928 (75.4) | 1970 (75.2) | .81 |
| HLA disparity (mismatch) | 6314 (60.2) | 4742 (60.3) | 1572 (60.0) | .77 |
| Conditioning (reduced intensity) | 2774 (26.5) | 2106 (26.8) | 668 (25.5) | .20 |
| Total body irradiation | 7521 (71.8) | 5688 (72.4) | 1833 (70.0) | .019 |
| GVHD prophylaxis | ||||
| Tacrolimus-based regimen | 7352 (70.2) | 5534 (70.4) | 1818 (69.4) | .32 |
| Mycophenolate mofetil use | 1154 (11.0) | 857 (10.9) | 297 (11.3) | .54 |
| TCD in vivo | 872 (8.3) | 676 (8.6) | 196 (7.5) | .072 |
| Transplant year | .67 | |||
| 2004-2010 | 3878 (37.0) | 2918 (37.1) | 960 (36.6) | |
| 2011-2016 | 6602 (63.0) | 4942 (62.9) | 1660 (63.4) |
| Variables . | All patients (N = 10 480) . | Training cohort (n = 7860) . | Test cohort (n = 2620) . | P . |
|---|---|---|---|---|
| Underlying disease | .35 | |||
| Acute myeloid leukemia | 5811 (55.4) | 4344 (55.3) | 1467 (56.0) | |
| Acute lymphoblastic leukemia | 2466 (23.5) | 1873 (23.8) | 593 (22.6) | |
| Myelodysplastic syndromes | 1801 (17.2) | 1333 (17.0) | 468 (17.9) | |
| CML | 402 (3.8) | 310 (3.9) | 92 (3.5) | |
| Patient age, median (range), y | 49 (18-70) | 49 (18-70) | 49 (18-70) | .44 |
| Patient age ≥50 y | 5154 (49.2) | 3861 (49.1) | 1293 (49.4) | .84 |
| Donor age, median (range), y | 33 (0-69) | 33 (0-69) | 33 (0-68) | .33 |
| Donor age ≥50 y | 1181 (11.3) | 889 (11.3) | 292 (11.1) | .83 |
| Patient sex, male | 6112 (58.3) | 4575 (58.2) | 1537 (58.7) | .70 |
| Donor sex, male | 6318 (60.3) | 4748 (60.4) | 1570 (59.9) | .66 |
| Female donor to male recipient | 2325 (22.2) | 1742 (22.2) | 583 (22.3) | .94 |
| Recipient/donor CMV serology | .75 | |||
| Positive/positive | 4329 (41.3) | 3236 (41.2) | 1093 (41.7) | |
| Positive/negative | 4201 (40.1) | 3143 (40.0) | 1058 (40.4) | |
| Negative/positive | 754 (7.2) | 575 (7.3) | 179 (6.8) | |
| Negative/negative | 1196 (11.4) | 906 (11.5) | 290 (11.1) | |
| Disease risk (high) | 4240 (40.5) | 3134 (39.9) | 1106 (42.2) | .036 |
| PS (poor) | 718 (6.9) | 563 (7.2) | 155 (5.9) | .029 |
| Stem cell source | .55 | |||
| Bone marrow | 5920 (56.5) | 4418 (56.2) | 1502 (57.3) | |
| PBSC | 1853 (17.7) | 1405 (17.9) | 448 (17.1) | |
| CB | 2707 (25.8) | 2037 (25.9) | 670 (25.6) | |
| Transplant from unrelated donor | 7898 (75.4) | 5928 (75.4) | 1970 (75.2) | .81 |
| HLA disparity (mismatch) | 6314 (60.2) | 4742 (60.3) | 1572 (60.0) | .77 |
| Conditioning (reduced intensity) | 2774 (26.5) | 2106 (26.8) | 668 (25.5) | .20 |
| Total body irradiation | 7521 (71.8) | 5688 (72.4) | 1833 (70.0) | .019 |
| GVHD prophylaxis | ||||
| Tacrolimus-based regimen | 7352 (70.2) | 5534 (70.4) | 1818 (69.4) | .32 |
| Mycophenolate mofetil use | 1154 (11.0) | 857 (10.9) | 297 (11.3) | .54 |
| TCD in vivo | 872 (8.3) | 676 (8.6) | 196 (7.5) | .072 |
| Transplant year | .67 | |||
| 2004-2010 | 3878 (37.0) | 2918 (37.1) | 960 (36.6) | |
| 2011-2016 | 6602 (63.0) | 4942 (62.9) | 1660 (63.4) |
Unless otherwise noted, all data are n (%).